Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression.

Lozada-Delgado EL, Grafals-Ruiz N, Miranda-Román MA, Santana-Rivera Y, Valiyeva F, Rivera-Díaz M, Marcos-Martínez MJ, Vivas-Mejía PE.

Cancers (Basel). 2018 Oct 12;10(10). pii: E382. doi: 10.3390/cancers10100382.

2.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

3.

RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mejía PE.

Life Sci. 2017 Nov 1;188:26-36. doi: 10.1016/j.lfs.2017.08.027. Epub 2017 Aug 31. Review.

4.

Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.

Báez-Vega PM, Echevarría Vargas IM, Valiyeva F, Encarnación-Rosado J, Roman A, Flores J, Marcos-Martínez MJ, Vivas-Mejía PE.

Oncotarget. 2016 Jun 14;7(24):36321-36337. doi: 10.18632/oncotarget.9216.

5.

Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?

Alcedo-Guardia R, Labat E, Blas-Boria D, Vivas-Mejia PE.

Curr Mol Med. 2016 Apr 29. [Epub ahead of print]

PMID:
26585986
6.

Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE.

Mol Cancer Ther. 2015 Oct;14(10):2260-9. doi: 10.1158/1535-7163.MCT-14-0801. Epub 2015 Jul 30.

7.

MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value.

Rivera-Díaz M, Miranda-Román MA, Soto D, Quintero-Aguilo M, Ortiz-Zuazaga H, Marcos-Martinez MJ, Vivas-Mejía PE.

Am J Cancer Res. 2014 Dec 15;5(1):201-18. eCollection 2015.

8.

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.

Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK.

Clin Cancer Res. 2015 Jan 15;21(2):448-59. doi: 10.1158/1078-0432.CCR-14-1578. Epub 2014 Nov 21.

9.

Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.

Echevarría-Vargas IM, Valiyeva F, Vivas-Mejía PE.

PLoS One. 2014 May 27;9(5):e97094. doi: 10.1371/journal.pone.0097094. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e116447.

10.

Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes.

Díaz MR, Vivas-Mejia PE.

Pharmaceuticals (Basel). 2013 Nov 4;6(11):1361-80. doi: 10.3390/ph6111361.

11.

Assessment of mRNA splice variants by qRT-PCR.

Vargas IM, Vivas-Mejía PE.

Methods Mol Biol. 2013;1049:171-86. doi: 10.1007/978-1-62703-547-7_13.

12.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.

13.

Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G.

Clin Cancer Res. 2011 Jun 1;17(11):3716-26. doi: 10.1158/1078-0432.CCR-11-0233. Epub 2011 Apr 21.

14.

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK.

Mol Cancer Ther. 2010 Aug;9(8):2377-88. doi: 10.1158/1535-7163.MCT-10-0200. Epub 2010 Aug 3.

15.

Sustained small interfering RNA delivery by mesoporous silicon particles.

Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M.

Cancer Res. 2010 May 1;70(9):3687-96. doi: 10.1158/0008-5472.CAN-09-3931.

16.

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK.

J Clin Invest. 2010 May;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

17.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

18.

Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.

Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G.

Int J Cancer. 2009 Jul 15;125(2):264-75. doi: 10.1002/ijc.24341.

19.

Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.

Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD.

Clin Cancer Res. 2008 Dec 15;14(24):8143-51. doi: 10.1158/1078-0432.CCR-08-1539.

20.

Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.

Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M.

Cancer Res. 2008 Nov 1;68(21):9078-86. doi: 10.1158/0008-5472.CAN-08-2397.

21.

Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.

Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM.

Oncogene. 2008 Dec 4;27(57):7192-200. doi: 10.1038/onc.2008.356. Epub 2008 Sep 22.

22.

Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.

Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK.

Cancer Res. 2008 Jul 15;68(14):5849-58. doi: 10.1158/0008-5472.CAN-07-6130.

23.

Hippocampal gene expression profiling in spatial discrimination learning.

Robles Y, Vivas-Mejía PE, Ortiz-Zuazaga HG, Félix J, Ramos X, Peña de Ortiz S.

Neurobiol Learn Mem. 2003 Jul;80(1):80-95.

PMID:
12737936
24.

Inhibition of human topoisomerase II by anti-neoplastic benzazolo[3,2-alpha]quinolinium chlorides.

Vivas-Mejía PE, Cox O, González FA.

Mol Cell Biochem. 1998 Jan;178(1-2):203-12.

PMID:
9546601
25.

DNA binding-independent anti-proliferative action of benzazolo[3,2-alpha]quinolinium DNA intercalators.

Vivas-Mejía PE, Rodríguez-Cabán JL, Díaz-Velázquez M, Hernández-Pérez MG, Cox O, Gonzalez FA.

Mol Cell Biochem. 1997 Dec;177(1-2):69-77.

PMID:
9450647

Supplemental Content

Loading ...
Support Center